Oncotarget, the internationally recognized and distinguished biomedical Journal has announced to all of its readers that their publications will continue to be available on several platforms such as Pubmed, Pubmed Centra, I/Web of Science: Science Citation Index Expanded, EMBUS, Biological Abstracts, BIOSIS Previews, and Scopus. Because of Oncotarget’s commitment to its cooperate the National Library of Medicine they are achieving its goal to become the world’s first research journal capable of submitting a complete issue to Pubmed just a few days after completion.
This news comes to the great relief to all high profile scientific texas and archives, the work diligently to make the results of scientific experiments widely available. In order to accelerate indexing processes, the company is now publishing two issues per week. This change comes specifically to boost the journal’s ability to adapt and change to new information the moment it becomes available, allowing researchers to continue their work in a seamless fashion, rather than waiting for new research to be published sporadically.
What’s notable about this change is that Oncotarget is now one of the most frequently and rapidly updated peer-reviewed open access biomedical journals which cover all research topics within oncology, as well as broader topics such as Aging, Immunology and Microbiology, Autophagy, and more.
A report by The Office of External & Legal Affairs of Oncotarget said, “We believe that it is necessary to meet the challenges of the 21st century, which is why our mission endures to be a scholarly journal well known for rapid and wide-scale dissemination of esteemed bio-medical research. Ultimately, Oncotarget is the journal by scientists for scientists,” and “will remain a resource to assist all researchers with their contribution to the progress of science as together we strive to see life without disease.”
It is great to see a modern medical journal acting as a truly 21st-century source of information. Rather than being stuck in an old-world classical journal publishing model with a long approval process and several delays, Oncotarget has chosen to deliver the latest discoveries and findings first and foremost, all while maintaining the same quality content and scrutiny in terms of article selection as ever before and more